Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Invested Capital (2021 - 2022)

Cartesian Therapeutics (RNAC) has disclosed Return on Invested Capital for 2 consecutive years, with 0.04% as the latest value for Q4 2022.

  • For Q4 2022, Return on Invested Capital fell 409.0% year-over-year to 0.04%; the TTM value through Dec 2022 reached 0.04%, down 409.0%, while the annual FY2025 figure was 2.01%, 180.0% up from the prior year.
  • Return on Invested Capital hit 0.04% in Q4 2022 for Cartesian Therapeutics, down from 0.13% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 4.13% in Q4 2021 and bottomed at 0.04% in Q4 2022.